Analyst Insights

Roth Capital Initiates Coverage On Prosensa At Neutral; Sets $12 Price Target

In a research note released this morning, Roth Capital analyst Debjit Chattopadhyay initiated coverage with a “Neutral” rating on Prosensa Holding N.V.

Superior Drilling Products Receives New Coverage From Analyst At Roth Capital

Roth Capital analyst Joseph Reagor initiated coverage on shares of Superior Drilling Products Co. (SDPI) in a research note issued this morning.

William Blair Maintains Outperform On TESSCO Technologies Following Discussions With Executives

In a research report issued this morning, William Blair analyst Anil Doradla maintained coverage with a “Market Perform” rating on TESSCO Technologies Incorporated (TESS) following discussions he has held with …

Seeking Alpha Article On Ligand Pharmaceuticals Just Foolish, Says Roth Capital Analyst

A bearish article published Monday afternoon on Seeking Alpha claimed that LGND stock has the potential to lose 100% of its value based …

Galena Reiterated With A Buy At Roth Capital Following Enrollment Completion In Phase IIa Study

In a research note issued earlier today, Roth Capital analyst Joseph Pantginis reiterated coverage with a “Buy” rating on Galena Biopharma, Inc. (GALE), and a …

Roth Capital Reiterates Buy Rating On Can-Fite Following The Completion Of Patients Enrollment

In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated coverage on Can-Fite Bio Pharma (CANF) with a Buy rating and a $28.00 price target.

Roth Capital Sees An Attractive Buying Opportunity In Motorcar Parts of America

In a research note issued today, Roth Capital analyst Philip Shen reiterated coverage with a “Buy” rating on Motorcar Parts of America, Inc. (MPAA), and a …

H.C. Wainwright Keeps ‘Buy’ On Ariad Following $200 Million Offering

In a research note issued today, H.C.

Agile Initiated With A Buy At Janney Capital; Considers AGRX A Compelling Investment

Janney Capital analyst Kimberly Lee is out today with an interesting call initiating Agile Therapeutics, Inc. (AGRX) with a Buy rating and $18 fair …

Roth Capital Reiterates Buy Rating On LeMaitre Vascular Following Recent Financing

In a research note issued this morning, Roth Capital analyst Chris Lewis reiterated coverage with a “Buy” rating on LeMaitre Vascular, Inc. (LMAT), and a price target of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts